Safety and efficacy of telitacicept in refractory systemic lupus erythematosus patients who failed treatment with belimumab : A  case series

CONCLUSION: This is the first case series in SLE patients who accepted telitacicept treatment after failed treatment with belimumab. Our case series and review of the literature show that telitacicept combined with the original standard treatment may significantly improve disease activity while reducing prednisone use. No major safety issues were seen in this group of patients. Telitacicept may be a promising drug for the treatment of refractory lupus hepatitis.PMID:38157053 | DOI:10.1007/s00393-023-01461-z
Source: Zeitschrift fur Rheumatologie - Category: Rheumatology Authors: Source Type: research